To enhance the oral bioavailability and eliminate the food effect of probucol. Probucol-phospholipid complex was prepared using solvent-evaporation method in this research. Several methods were used to validate the formation of complexes, such as FT-IR, SEM, DSC and PXRD, and the solubility of PRO and PRO-PLC was detected by HPLC. Pharmacokinetic testing was conducted in the fasted and fed state. FTIR, SEM, DSC and PXRD validated the existence of PRO-PLC. The solubility of PRO in complexes was 15.05 μg/mL, which was 215-fold of the PRO-API. The dissolution rate was increased by preparing PRO-PLC. Compared with commercial tablets, the PRO-PLC complexes exhibited higher peak plasma concentration (1.69 ± 0.44 μg/mL), increased AUC0–24 h (6.8 ± 1.3 μg/mL h), which mean the bioavailability of PRO was increased. In addition, the absorption of PRO was not interfered with food. In conclusion, an improved solubility and bioavailability was achieved with the preparation of PRO-PLC. Additionally, the dissolution behaviour was good and the food effect was eliminated.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Kubo Y, Terashima Y, Yagi N, Nochi H, Tamoto K, Sekikawa H. Enhanced bioavailability of probucol following the administration of solid dispersion systems of probucol-polyvinylpyrrolidone in rabbits. Biol Pharm Bull. 2009;32:1880–4.
Shudo J, Pongpeerapat A, Wanawongthai C, Moribe K, Yamamoto K. In vivo assessment of oral administration of probucol nanoparticles in rats. Biol Pharm Bull. 2008;31:321–5.
Russell JC, Graham SE, Amy RM, Dolphin PJ. Cardioprotective effect of probucol in the atherosclerosis-prone JCR LA-cp rat. Eur J Pharmacol. 1998;350:203–10.
Zaitseva TM, Lupanov VP, Lyakishev AA, Titov VN, Polevaya TY. Pharmacokinetics of probucol dosage forms in clinical tests. Pharma Chem. 1995;29:21–3.
Heeg JF, Hiser MF, Satonin DK, Rose JQ. Pharmacokinetics of probucol in male rats. J Pharm Sci. 1984;73:1758–63.
Io T, Fukami T, Yamamoto K, Suzuki T, Xu JD, Tomono K. Homogeneous nanoparticles to enhance the efficiency of ahydrophobic drug anti-hyperlipidemic probucol characterized by solid-state NMR. Mol Pharm. 2009;7:1–12.
Nielsen FS, Petersen KB, Mullertz A. Bioavailability of probucol from lipid and surfactant based formulations in minipigs: influence of droplet size and dietary state. Eur J Pharm Biopharm. 2008;69:553–62.
Xianyi S, Juan W, Yanzuo C, Xiaoling F. Self-microemulsifying drug delivery system for improved oral bioavailability of probucol: preparation and evaluation. Int J Nanomedicine. 2012;7:705–12.
Miao Y, Chen G, Ren L. Preparation and evaluation of ziprasidone-phospholipid complex from sustained-release pellet formulation with enhanced bioavailability and no food effect. J Pharm Pharmacol. 2016;68(2):185–94.
Singh C. Novel rifampicinphospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. Int J Pharm. 2014;460:220–7.
Gupta NK. Bioavailability enhancement of curcumin by complexation with phosphatidylcholine. J Pharm Sci. 2011;100:1987–95.
Yu JN. Enhancement of oral bioavailability of the poorly water soluble drug silybin by sodium cholate/phospholipid-mixed micelles. Acta Pharmacol Sin. 2010;31:759–64.
Hequn M. Improving permeability and oral absorption of mangiferin by phospholipid complexation. Fitoterapia. 2014;93:54–61.
Khan J, Alexander A, Ajazuddin Saraf S, Saraf S. Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives. J Control Release. 2013;168:50–60.
Afanaseva YG, Fakhretdinova ER, Spirikhin LV, Nasibullin RS. Mechanism of interaction of certain flavonoids with phosphatidylcholine of cellular membranes. Pharm Chem J. 2007;41:354–6.
Mezghrani O, Ke X, Bourkaib N, Xu BH. Optimized self-microemulsifying drug delivery systems (SMEDDS) for enhanced oral bioavailability of astilbin. Pharmazie. 2011;66:754–60.
National Pharmacopoeia Commission. “Chinese Pharmacopoeia 2015” version II [S]. Beijing: China Medical Sci Technol Press; 2015. Appendix XI XC Guidelines for Stability Testing of APIs and Pharmaceutical Preparations.
Kim Y. Inclusion complexation of ziprasidone mesylate with beta-cyclodextrin sulfobutyl ether. J Pharm Sci. 1998;87:1560–7.
Bei G. Application of phospholipid complex technique to improve the dissolution and pharmacokinetic of probucol by solvent-evaporation and co-grinding methods. Int J Pharm. 2014;474:50–6.
Jena SK. Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability. Int J Pharm. 2014;473:1–9.
Semalty A. Development and physicochemical evaluation of pharmacosomes of diclofenac. Acta Pharma. 2009;59:335–44.
Yanyu X. The preparation of silybin phospholipid complex and the study on its pharmacokinetics in rats. Int J Pharm. 2006;307:7–82.
Guest Editor: Sanyog Jain
About this article
Cite this article
Qian, Y., Chen, G., Wang, J. et al. Preparation and Evaluation of Probucol-Phospholipid Complex with Enhanced Bioavailability and No Food Effect. AAPS PharmSciTech 19, 3599–3608 (2018). https://doi.org/10.1208/s12249-018-1157-2
- food effect
- phospholipid complex